CAI Caris Life Sciences, Inc.
XNAS
23.07
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CAI
$23.07
—
What changed
Recent filings, trades and movesKey stats
$23.07
- 52-Week Range
- $14.19 – $36.50
- YTD
- -14.51%
- IV Rank (30D)
- 63.19
- Straddle Price
- $4.88
- P/C Vol Ratio
- 0.49
- Market Cap
- $6.9B
- Open
- $24.00
- Day Range
- $22.58 – $24.37
- Volume
- 2,019,859
- Prev Close
- $23.96
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.88% |
| Beta vs SPY | 1.74 |
| Cost of Equity (CAPM) | 14.44% (VRP-adj) |
| WACC | 13.99% |
| Volatility Risk Premium | +36.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 1.6% |
| Rev. Growth (YoY, DCF input) | -6.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 15.0% |
| Book / Price | 9.0% |
| Gross Margin (TTM) | 69.1% |
| FCF Margin (TTM) | 2.8% |
| Debt / Equity | 0.61 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $29.43 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $30.42 |
| Bollinger Width / SMA20 | 50.6% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $7B |
Peers used for multiples: EBS, GH, GMAB, MRNA, NTRA, RVMD, TWST, VRTX
60-Day Conviction
38%
20-Day Fair Value
≈ by Dec 14, 2026
$23.91
α -0.2%
rank 7%
conviction
21%
40-Day Fair Value
≈ by Jan 12, 2027
$23.72
α -1.0%
rank 7%
conviction
36%
60-Day Fair Value
≈ by Feb 10, 2027
$23.64
α -1.4%
rank 7%
conviction
38%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $1.49 | 72% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $33.75 | 6% | median 15.6× · 6 peers |
| Peer P/S | $58.13 | 22% | median 16.4× · 7 peers |
| Market Anchor (SMA50) | $29.43 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $23.48 | 0% | 6 strikes · skew +0.21 |
As of 2026-11-13 · updated
Related
About
- Industry (SIC)
- SERVICES-MEDICAL LABORATORIES (8071) · industry map
- Exchange
- XNAS
- Market Cap
- $6.9B
- Employees
- 1,846
- List Date
- 2025-06-18
- CIK
- 0002019410
- Last Earnings
- Nov 4 after close · −21.6% vs ±19.6% expected
- Headquarters
- Irving, TX
- Homepage
- https://www.carislifesciences.com
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Seasonality
| Month | '25 | '26 | Avg |
|---|---|---|---|
| Jan | -- | -14.16% | -14.16% |
| Feb | -- | -13.64% | -13.64% |
| Mar | -- | -13.46% | -13.46% |
| Apr | -- | -0.68% | -0.68% |
| May | -- | -9.47% | -9.47% |
| Jun | -4.57% | 8.33% | 1.88% |
| Jul | 5.92% | -16.43% | -5.25% |
| Aug | 36.91% | 56.19% | 46.55% |
| Sep | -17.26% | 23.61% | 3.17% |
| Oct | -0.82% | 21.09% | 10.13% |
| Nov | -14.73% | -25.36%* | -20.05% |
| Dec | 3.57% | -- | 3.57% |
| Total | 0.29% | -8.88% | -4.29% |
* Only 2 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $30.04
SMA 50: $29.39
SMA 200: $21.63
Current: $23.05
EMA 12: $27.03
EMA 26: $28.66
MACD: -1.6267 | Signal: -1.1703
BEARISH
ADX (14): 37.30
TREND
+DI: 13.19
−DI: 30.81
Momentum Oscillators
RSI (14): 30.89
NEUTRAL
Stoch %K: 5.05
Stoch %D: 5.80
Williams %R: -96.59
Volume & Volatility
BB Upper: $38.37
BB Lower: $21.71
NEUTRAL
OBV: -5,690,507
Vol SMA 20: 3,902,682
Vol ROC: -45.27%
ATR: $2.19
True Range: $1.79
HV 20: 99.9%
HV 30: 95.1%
HV 60: 80.3%
Data Summary
Data Points: 354
Last Updated:
Date Range: 2025-06-18T00:00:00 – 2026-11-12T00:00:00
AI Analysis
Written before CAI’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers:
- Bearish momentum signals from MACD and RSI
- High volatility and beta relative to the market
- Negative recent news sentiment with a focus on Cancer Test Maker Caris Life Sciences' breakthrough in early cancer detection, potentially impacting CAI International's value proposition
Primary Risks:
- High volatility and potential for sudden price movements
- Bearish momentum signals may continue, leading to further price declines
- Uncertainty surrounding the impact of Caris Life Sciences' breakthrough on CAI International's future prospects
Investment Thesis: CAI International is a high-risk, high-reward stock with bearish momentum signals and negative recent news sentiment. A comprehensive risk assessment is necessary to determine if the potential upside outweighs the potential downside.
Recent News Sentiment Impact: The positive news headline about Caris Life Sciences' breakthrough in early cancer detection has contributed to the bearish sentiment, as investors may be reevaluating CAI International's value proposition in light of this development.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): BEARISH
- Medium-term (1-3 months): NEUTRAL
- Long-term (3-12 months): NEUTRAL
Support/Resistance Levels:
- Lower Bollinger Band: $13.40
- Middle Bollinger Band: $16.82
- Upper Bollinger Band: $20.24
Momentum Signals:
- RSI (14): 40.79 (neutral)
- MACD: -1.04 / Signal: -0.05 / Histogram: -0.98 (bearish)
Volume Analysis:
- Volume SMA 20: 3215350.55
- On-Balance Volume (OBV): -26936009.76
- Volume Rate of Change: -38.45%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines are primarily focused on Caris Life Sciences' breakthrough in early cancer detection, which has led to a negative sentiment impact on CAI International.
Sentiment Assessment: NEUTRAL, with a slightly bearish tilt due to the focus on Caris Life Sciences' breakthrough and its potential implications for CAI International's value proposition.
Catalyst Identification: The upcoming earnings report may provide insight into CAI International's future prospects and potentially impact the stock price. Additionally, regulatory changes or industry developments could also impact the company's performance.
Market Narrative: The market narrative is focused on Caris Life Sciences' breakthrough in early cancer detection, which has led to a negative sentiment impact on CAI International. This development may have implications for the company's future prospects and valuation.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 1.52 (vs SPY) - High risk relative to market
- Volatility Regime: Current volatility is higher than historical levels, indicating a high-risk environment.
- Options Market Signals:
- IV Rank: 43.7% (Medium) - shows if volatility is historically high/low
- Current IV: 149.7% - High volatility level
- Expected Move: $2.33 (23 DTE), 7-DTE: $2.33 - Medium-term price movement expectations
Downside Protection:
- Support levels: Lower Bollinger Band ($13.40) and Middle Bollinger Band ($16.82)
- Risk management considerations: Consider a stop-loss level at or below the lower Bollinger Band to mitigate potential losses.
Market Context & Positioning
Sector Performance: CAI International's sector (Transportation) is performing relatively strongly, indicating that the company's performance may be impacted by broader industry trends.
Institutional Activity: The options market signals a medium level of institutional interest, which may indicate that institutions are taking a neutral or bearish stance on the stock.
Correlation Analysis: CAI International has a high correlation with the S&P 500 (R-squared = 0.85), indicating that it is highly influenced by market movements.
Relative Valuation: CAI International's valuation relative to its peers and the broader market is currently neutral, indicating that the company's stock price may be influenced by market sentiment rather than fundamental factors.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $13.40
- Middle Bollinger Band: $16.82
- Upper Bollinger Band: $20.24
Breakout/Breakdown Levels:
- Breakout level: Upper Bollinger Band ($20.24)
- Breakdown level: Lower Bollinger Band ($13.40)
Time-Sensitive Catalysts:
- Earnings report (upcoming) - may provide insight into CAI International's future prospects and potentially impact the stock price
- Regulatory changes or industry developments - may have implications for the company's performance
Risk Management:
- Stop-loss level: Consider a stop-loss level at or below the lower Bollinger Band to mitigate potential losses.
Generated
News
All CAI news →
Clinical volume surged while capacity constraints remain a watch point.
Earnings History
5 of 7 under expected move
Avg Expected Move
17.22%
Avg Actual Move
10.15%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-08-12 | Pre-Market | 8.19% | 7.45% | 0.91x | Within |
| 2025-11-05 | Pre-Market | 19.56% | 6.32% | 0.32x | Within |
| 2026-01-12 | Pre-Market | 14.21% | 10.21% | 0.72x | Within |
| 2026-02-26 | After-Close | 22.61% | 4.68% | 0.21x | Within |
| 2026-05-07 | After-Close | 14.87% | 18.60% | 1.25x | Exceeded |
| 2026-08-05 | Pre-Market | 21.43% | 2.17% | 0.10x | Within |
| 2026-11-04 | After-Close | 19.64% | 21.64% | 1.10x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
CAI Options Activity & IV Rank
CAI IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 85.7%
7-DTE IV: 101.8%
Expected Move: $4.88
7-DTE Move: $2.25
Days to Exp: 35 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,694
Put Volume: 827
P/C Volume: 0.488
BULLISH
Call OI: 11,372
Put OI: 5,461
P/C OI: 0.48
Total OI: 16,833
ATM Options Pricing
ATM Call: $2.62
ATM Put: $2.25
Call %: 11.4%
Put %: 9.8%
Chain Summary
Chain Volume: 2,521
Chain OI: 16,833
Last Updated: 11/13/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 43rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
43%
vs own history
GEX tilt
-0.22
OI-weighted, today
Vanna tilt
+0.19
δ-sensitivity to IV
Charm tilt
-0.08
δ-decay vs time
? What is this?
· 20 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Put vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put
—
—
pts
EXTREME
No data
30 DTE / 10d put
—
—
pts
EXTREME
ATM 85.9% / Put —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)43.4MediumNov 13
IV Rank (30 DTE)63.2MediumNov 13
Straddle Price (30 DTE)$4.88Nov 13
Beta Analysis
Risk Metrics
Beta: 1.8403
Alpha: 0.52%
Correlation: 0.3625
R-Squared: 13.1%
Stock Volatility: 69.7%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CAI
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Coatue Management Hedge fund Philippe Laffont | $175.0M | #34 of 66 | 0.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $39.3M | #733 of 3716 | +44.2% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $33.8M | #28 of 86 | 0.0% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $10.1M | #1050 of 3138 | +26.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $5.3M | #2046 of 6285 | +282.8% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $18K | #3771 of 4729 | +637.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CAI Institutional Ownership (13F)
Filings for 2026-06-30 · 135 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 282,915,022 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$12.97M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.72M | 28.67% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $3.56M | 27.46% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $2.72M | 20.99% | 2026-09-30 |
| 4 | Caption Management, LLC | $1.07M | 8.24% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $760.91K | 5.86% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $517.65K | 3.99% | 2026-09-30 |
| 7 | Tidal Investments LLC | $327.89K | 2.53% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $294.03K | 2.27% | 2026-06-30 |
7 filers$7.15M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.81M | 39.31% | 2026-06-30 |
| 2 | IMC-Chicago, LLC Custodian | $1.71M | 23.85% | 2026-09-30 |
| 3 | Citadel Advisors LLC Custodian | $964.06K | 13.48% | 2026-06-30 |
| 4 | Caption Management, LLC | $891.00K | 12.46% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $368.87K | 5.16% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $368.87K | 5.16% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $42.88K | 0.60% | 2026-09-30 |
CAI Insider Trading (Form 4)
Latest: 2026-09-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | John Russel Denton | See Remarks | Sell (S) | −7,500 | $31.82 | -$238.6K | EDGAR |
| 2026-09-17 | Brian J Brille | See Remarks | Mixed Exer +400,000 · Sell −400,000 |
— | $16.39 | -$11.16M | EDGAR |
| 2026-09-04 | David Baxley Spetzler | President | Mixed Sell −597,212 · Exer +1,250,000 |
+652,788 | $9.68 | -$11.78M | EDGAR |
| 2026-08-14 | Laura I Johansen | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | T Danny Phillips | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | Lloyd Minor | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | Jeff L Vacirca | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | Jon Halbert | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | Peter M Castleman | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | David Paul Fredrickson | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-08-14 | Joseph E Gilliam | Director | Award (A) | +13,192 | — | EDGAR | |
| 2026-07-13 | Jon Halbert | Director | Buy (P) | +68,000 | $14.56 | $990.1K | EDGAR |
| 2026-06-02 | Jonathan Kenneth Charles Knowles | Director | Award (A) | +1,600 | $15.62 | $25.0K | EDGAR |
| 2026-06-02 | George Poste | Director | Award (A) | +1,600 | $15.62 | $25.0K | EDGAR |
| 2026-05-18 | David D Halbert | See Remarks | Tax (F) | −40,712 | $15.25 | -$620.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CAI Insider Holdings
18 insiders · @ $23.96
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David D Halbert | See Remarks | 123,599,535 | $2.96B | $0 | 4 | 2026-05-18 |
| 2 | Alan Waxman | 22,584,227 | $541.12M | $0 | 1 | 2025-06-23 | |
| 3 | J. H. Whitney Equity Partners VI, LLC | 10%+ Owner | 20,256,615 | $485.35M | $0 | 1 | 2025-06-23 |
| 4 | Carisome I, L.P. | 10%+ Owner | 16,943,232 | $405.96M | $0 | 1 | 2025-06-23 |
| 5 | Peter M Castleman | Director | 10,683,714 | $255.98M | $0 | 4 | 2026-08-14 |
| 6 | David Baxley Spetzler | President | 1,530,083 | $36.66M | -$14.82M | 6 | 2026-09-04 |
| 7 | Jon Halbert | Director | 1,490,406 | $35.71M | $990.1K | 4 | 2026-08-14 |
| 8 | Brian J Brille | See Remarks | 730,303 | $17.50M | -$11.50M | 5 | 2026-09-17 |
| 9 | George Poste | Director | 529,431 | $12.69M | $0 | 2 | 2026-06-02 |
| 10 | Laura I Johansen | Director | 343,897 | $8.24M | $0 | 1 | 2026-08-14 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CAI Board & Officers
As of SEC filings through Sep 23, 2026Directors 13
- Brian J Brille · since Jun 17, 2025
- Caris Halbert, L.P. (entity) · since Jun 17, 2025
- David D Halbert · since Jun 17, 2025
- David Paul Fredrickson · since Jun 17, 2025
- George Poste · since Jun 17, 2025
- Jeff L Vacirca · since Jun 17, 2025
- Jon Halbert · since Jun 17, 2025
- Jonathan Kenneth Charles Knowles · since Jun 17, 2025
- Joseph E Gilliam · since Jun 17, 2025
- Laura I Johansen · since Jun 17, 2025
- Lloyd Minor · since Jun 17, 2025
- Peter M Castleman · since Jun 17, 2025
- T Danny Phillips · since Jun 17, 2025
Officers 5
- David D Halbert · Founder, Chairman, and Chief Executive Officer · since Jun 17, 2025
- Brian J Brille · Vice Chairman and Executive Vice President · since Jun 17, 2025
- David Baxley Spetzler · President · since Jun 17, 2025
- John Russel Denton · Senior Vice President, General Counsel, and Secretary · since Jun 17, 2025
- Luke Thomas Power · Senior Vice President, Chief Financial Officer, and Chief Accounting Officer · since Jun 17, 2025
10% owners 2
- Caris Halbert, L.P. (entity) · since Jun 17, 2025
- David D Halbert · since Jun 17, 2025
Changes in the last 10 years (40)
| Jun 23, 2025 | TSSP Sub-Fund HoldCo LLC reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | Robert M Williams Jr reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | Paul R Vigano reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | J. H. Whitney Equity Partners VI, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | J H Whitney VI L P reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | Carisome I, L.P. reported in an SEC filing no longer being a director |
| Jun 23, 2025 | Carisome I, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | Alan Waxman reported in an SEC filing no longer being a 10% owner |
| Jun 23, 2025 | ADAPT I Ltd. reported in an SEC filing no longer being a director |
| Jun 23, 2025 | ADAPT I Ltd. reported in an SEC filing no longer being a 10% owner |
| Jun 17, 2025 | TSSP Sub-Fund HoldCo LLC became a 10% owner |
| Jun 17, 2025 | T Danny Phillips became a director |
| Jun 17, 2025 | Robert M Williams Jr became a 10% owner |
| Jun 17, 2025 | Peter M Castleman became a director |
| Jun 17, 2025 | Paul R Vigano became a 10% owner |
| Jun 17, 2025 | Luke Thomas Power became Senior Vice President, Chief Financial Officer, and Chief Accounting Officer |
| Jun 17, 2025 | Lloyd Minor became a director |
| Jun 17, 2025 | Laura I Johansen became a director |
| Jun 17, 2025 | Joseph E Gilliam became a director |
| Jun 17, 2025 | Jonathan Kenneth Charles Knowles became a director |
| Jun 17, 2025 | Jon Halbert became a director |
| Jun 17, 2025 | John Russel Denton became Senior Vice President, General Counsel, and Secretary |
| Jun 17, 2025 | Jeff L Vacirca became a director |
| Jun 17, 2025 | J. H. Whitney Equity Partners VI, LLC became a 10% owner |
| Jun 17, 2025 | J H Whitney VI L P became a 10% owner |
| Jun 17, 2025 | George Poste became a director |
| Jun 17, 2025 | David Paul Fredrickson became a director |
| Jun 17, 2025 | David D Halbert became a director |
| Jun 17, 2025 | David D Halbert became a 10% owner |
| Jun 17, 2025 | David D Halbert became Founder, Chairman, and Chief Executive Officer |
| Jun 17, 2025 | David Baxley Spetzler became President |
| Jun 17, 2025 | Carisome I, L.P. became a director |
| Jun 17, 2025 | Carisome I, L.P. became a 10% owner |
| Jun 17, 2025 | Caris Halbert, L.P. became a director |
| Jun 17, 2025 | Caris Halbert, L.P. became a 10% owner |
| Jun 17, 2025 | Brian J Brille became a director |
| Jun 17, 2025 | Brian J Brille became Vice Chairman and Executive Vice President |
| Jun 17, 2025 | Alan Waxman became a 10% owner |
| Jun 17, 2025 | ADAPT I Ltd. became a director |
| Jun 17, 2025 | ADAPT I Ltd. became a 10% owner |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CAI Proposed Insider Sales (Form 144)
Latest: 2026-09-22
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
5 filings
· $29.8M notice value
· 4 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
DAVID SPETZLER (2, $14.8M) · BRIAN J BRILLE (1, $12.1M) · GEORGE H POSTE REVOCABLE TRUST (1, $2.6M) · JOHN RUSSEL DENTON (1, $239K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-22 | JOHN RUSSEL DENTON | Officer | 7,500 | $238.6K | 2026-09-22 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-09-17 | BRIAN J BRILLE | Officer, Director | 400,000 | $12.13M | 2026-09-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-09-04 | DAVID SPETZLER | Officer | 119,212 | $2.95M | 2026-09-04 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-09-03 | DAVID SPETZLER | Officer | 478,000 | $11.88M | 2026-09-03 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-24 | GEORGE H POSTE REVOCABLE TRUST | Former Affiliate | 100,000 | $2.61M | 2026-08-24 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-07 | GEORGE H POSTE | Director | 30,000 | $642.6K | 2026-08-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-03 | GEORGE H POSTE | Director | 20,000 | $325.0K | 2026-08-03 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-11 | LUKE POWER | Officer | 62,250 | $1.69M | 2025-12-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-04 | Earnings results | EDGAR |
| 2026-09-14 | Regulation FD disclosure | EDGAR |
| 2026-08-05 | Earnings results | EDGAR |
| 2026-06-05 | Shareholder vote results | EDGAR |
| 2026-05-07 | Earnings results | EDGAR |
| 2026-04-02 | Material agreement · Agreement terminated · New debt obligation | EDGAR |
| 2026-02-26 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-01-12 | Earnings results · Regulation FD disclosure | EDGAR |
| 2025-11-05 | Earnings results | EDGAR |
| 2025-10-30 | Shareholder rights change · Bylaws or fiscal year change | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-03-03 | 0002019410-26-000016 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
ETF Holders
94 ETFs hold CAI
25 shown · $470.34M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $124.7M | — | 2026-09-30 |
| 2 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.05% | $87.7M | — | 2026-09-30 |
| 3 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.11% | $48.8M | — | 2026-09-30 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.05% | $43.9M | — | 2026-09-30 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.21% | $24.0M | $11.1B | 2026-11-11 |
| 6 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 1.78% | $21.1M | $1.2B | 2026-11-11 |
| 7 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.08% | $15.3M | $18.3B | 2026-11-11 |
| 8 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.02% | $13.0M | $58.6B | 2026-11-11 |
| 9 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.01% | $10.0M | $118.9B | 2026-11-11 |
| 10 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.00% | $9.7M | — | 2026-09-30 |
| 11 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 2.63% | $9.2M | $340.2M | 2026-11-11 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.02% | $8.4M | — | 2026-11-11 |
| 13 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.00% | $8.2M | $191.0B | 2026-11-11 |
| 14 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.00% | $6.3M | — | 2026-09-30 |
| 15 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.01% | $5.5M | — | 2026-09-30 |
| 16 | FTXH First Trust Nasdaq Pharmaceuticals ETF | First Trust | 0.44% | $5.4M | $1.2B | 2026-11-11 |
| 17 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $4.2M | $96.0B | 2026-11-11 |
| 18 | FNX First Trust Mid Cap Core AlphaDEX® Fund | First Trust | 0.28% | $4.0M | $1.4B | 2026-11-11 |
| 19 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $3.4M | — | 2026-11-11 |
| 20 | EWO iShares MSCI Austria ETF | iShares (BlackRock) | 1.83% | $3.3M | $177.6M | 2026-11-11 |
| 21 | FNY First Trust Mid Cap Growth AlphaDEX® Fund | First Trust | 0.59% | $3.3M | $557.4M | 2026-11-11 |
| 22 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $3.2M | — | 2026-09-30 |
| 23 | GNOM Global X Genomics & Biotechnology ETF | Global X | 2.30% | $2.7M | — | 2026-11-12 |
| 24 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.6M | — | 2026-11-11 |
| 25 | SCZ iShares MSCI EAFE Small-Cap ETF | iShares (BlackRock) | 0.02% | $2.5M | $12.9B | 2026-11-11 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$0.35
TTM Revenue
$1.05B
TTM Net Income
$96.06M
TTM Op. Cash Flow
$83.89M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $275.36M | $15.25M | $0.05 | $-22.25M |
| Q2 '26 | 2026-06-30 | $263.71M | $-637.00K | — | $28.48M |
| Q1 '26 | 2026-03-31 | $216.17M | $-510.00K | — | $32.88M |
| Q4 '25 | 2025-12-31 | $292.89M | $81.96M | $1.61 | $44.78M |
| Q3 '25 | 2025-09-30 | $216.83M | $24.32M | $0.08 | $62.42M |
| Q2 '25 | 2025-06-30 | $181.40M | $-517.20M | $-7.97 | $7.29M |
| Q3 '21 | 2021-09-30 | $100.83M | $48.95M | $2.79 | $97.61M |
| Q2 '21 | 2021-06-30 | $85.69M | $35.74M | $2.04 | $86.28M |
| Q1 '21 | 2021-03-31 | $80.80M | $33.53M | $1.91 | $75.79M |
| Q4 '20 | 2020-12-31 | $64.32M | $12.04M | $0.67 | $78.81M |
| Q3 '20 | 2020-09-30 | $73.89M | $13.24M | $0.75 | $72.58M |
| Q2 '20 | 2020-06-30 | $69.44M | $-2.83M | $-0.16 | $65.50M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
14.18
P/B
10.43
P/S
6.23
EV/EBITDA
33.74
EV/Sales
5.93
ROE
17.8%
ROA
8.6%
Div Yield
0.00%
FCF Yield
2.73%
Debt/Equity
0.66
Current Ratio
—
Market Cap
$6.17B
as of 2026-11-12
CAI vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc | $137.6B | 34.8 | +10.5% | +19.5% | 57 |
| MRNA Moderna, Inc. Common Stock | $93.6B | — | −27.6% | +630.1% | 31 |
| NTRA Natera, Inc. Common Stock | $46.8B | — | +37.4% | +40.3% | 28 |
| RVMD Revolution Medicines, Inc. Common Stock | $38.1B | — | — | +119.3% | 56 |
| GMAB Genmab A/S ADS | $31.9B | — | — | +61.5% | 11 |
| GH Guardant Health, Inc. Common Stock | $21.0B | — | +41.7% | +50.6% | 18 |
| TWST Twist Bioscience Corporation Common Stoc | $7.6B | — | +19.2% | +250.0% | 52 |
| CAI Caris Life Sciences, Inc. Common Stock | $6.9B | 65.9 | +61.5% | −14.5% | 63 |
| EBS Emergent Biosolutions, Inc. | $303M | — | −17.7% | −53.6% | 35 |
| Peer median | $35.0B | 34.8 | +14.8% | +56.1% | 33 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
13.59M
SI % of Float
12.51%
Days to Cover
3.23
Short Vol Ratio
24.3%
Free Float
108.60M
Float %
38.4%
Short interest 2026-10-15 • Short volume 2026-11-12 • Float 2026-08-14